Pharsight

Neurelis Inc patents expiration

1. Valtoco patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265402 NEURELIS INC Absorption enhancers for drug administration
May, 2025

(1 year, 7 months from now)

US9642913 NEURELIS INC Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
May, 2025

(1 year, 7 months from now)

US8927497 NEURELIS INC Absorption enhancers for intranasal administration
Jul, 2025

(1 year, 9 months from now)

US8895546 NEURELIS INC Administration of benzodiazepine compositions
Mar, 2029

(5 years from now)

US11241414 NEURELIS INC Administration of benzodiazepine compositions
Mar, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 10, 2027
New Product (NP) Jan 10, 2023

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older

Dosage: SPRAY;NASAL

More Information on Dosage

VALTOCO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic